Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Could See Generalized Anxiety Disorder Indication For Cymbalta In Early 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly submitted the sNDA for duloxetine’s new indication under a standard review.

You may also be interested in...



Cymbalta Buoyed By Branded Ad Campaign

Sales of Lilly’s antidepressant more than doubled in the first quarter.

GAO Urges Congress To Place EPO, Other Dialysis Services In Bundled Rates

The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.

Medicare’s Overdue Study On Changing EPO Payment Now Promised For 2007

A rapid change in Medicare policy on reimbursement for Amgen's Epogen (epoetin alfa) used in dialysis facilities is unlikely, despite impassioned criticism of the current policy from outgoing House Ways and Means Committee Chairman Bill Thomas (R-Calif.)

Topics

UsernamePublicRestriction

Register

PS064288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel